We compared the prevalence of a baseline diagnosis of cancer in patients with and without misty mesentery (MM) and determined its association with the development of a new cancer. This was a retrospective, HIPAA-compliant, IRB-approved case-control study of 148 cases and 4:1 age- and gender-matched controls. Statistical tests included chi-square, t-test, hazard models, and C-statistic. Patients with MM were less likely to have cancer at baseline (RR=0.74, p=0.003), but more likely to develop a new malignancy on follow-up (RR=2.13, p=0.003; survival analysis HR 1.74, p=0.05). MM may confer an increased probability of later developing cancer, particularly genitourinary tumors.
Keywords: CT; Cancer; Misty mesentery.
Copyright © 2017 Elsevier Inc. All rights reserved.